Ifosym 1g Injection

Mesna, a uroprotective agent, is co-administered to mitigate the urothelial toxicity associated with Ifosfamide, particularly hemorrhagic cystitis, by binding to and detoxifying acrolein, a toxic metabolite of Ifosfamide excreted in the urine. Ifosym 1g Injection is primarily utilized in the treatment of various malignancies including sarcomas, lymphomas, and testicular cancer, often as part of combination chemotherapy regimens.

The injection is administered intravenously under strict medical supervision, with dosing individualized based on patient-specific factors such as body surface area, renal function, and treatment response. Close monitoring for potential adverse effects including myelosuppression, neurotoxicity, nephrotoxicity, and electrolyte imbalances is essential. Adequate hydration and Mesna dosing are critical to reduce urothelial toxicity.

Ifosym 1g Injection should be handled and administered by trained healthcare professionals experienced in chemotherapy management to optimize therapeutic outcomes and minimize risks.